

14th February, 2025

The Deputy Manager,
Department of Corporate Services,
BSE Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai - 400001.

Scrip Code: 507486 (BSE)

Dear Sir,

Subject: Submission of the unaudited financial results for Quarter ended, 31st December, 2024

1. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Statement of Unaudited Standalone Financial Results for the quarter ended December 31, 2024 along with Limited Review Report submitted by the Statutory Auditors of the Company. The above financial results were upon recommendation of the Audit Committee approved by the Board of Directors at its meeting held on February 14th, 2025. The meeting of the Board of Directors of the Company commenced at 4:00 p.m. and concluded at 5:00 p.m.

Kindly take the same on your record.

We request you to inform your members accordingly.

Thanking you.

Yours faithfully,

For Caprolactam Chemicals Limited



Zaver Shankarlal Bhanushali
Managing Director
DIN: 00663374





PULINDRA PATEL & CO.
CHARTERED ACCOUNTANTS

Office No. A-1004, Paras Business Center, Kasturba Road No.1, Near Borivali Station East, Borivali East, Mumbai – 400 066,
Office (Tel) +022-28069664,022-22056233,022-68844594,+91-9322268243,Office (M) +91-9619908533
Email : caoffice@pulindrapatel.com, pulindra_patel@hotmail.com

Independent Auditor's Review Report on the Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors,
Caprolactam Chemicals Limited
Plot No. B-31, M.I.D.C.- Mahad,
Taluka – Mahad,
Dist Raigad – 402302.

We have reviewed the quarterly unaudited standalone financial results of **M/S.CAPROLACTAM CHEMICALS LIMITED** (the company) for the, Quarter ended December 31, 2024 and year to date results for the period from 1st April, 2024 to 31st December, 2024 (the Statement”) together with the Unaudited Statement of Assets and Liabilities, Unaudited Statement of Cash Flows attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 as amended (“Listing Regulations”).

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the Statement in accordance with the standard on Review Engagement (SRE) 2410 ‘Review of Interim Financial Information performed by the Independent Auditor of the Entity’ issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial



data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian accounting standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PULINDRA PATEL & CO.
CHARTERED ACCOUNTANTS
FIRM REGN. NO. 115187W



Pulindra M. Patel



Place: Mumbai
Date : 14th February, 2025

PULINDRA PATEL
MEMBERSHIP No. 048991
UDIN: 25048991BM IAYC5953

Caprolactam Chemicals Limited
CIN No. L24110MH1988PLC049683
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2024

PART I		(Rs. In Lakhs)					
		Quarter Ended			Nine Months Ended		Year Ended
		(Unaudited)			(Unaudited)		(Audited)
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
1	Revenue From Operation						
	Revenue from Operations	229.38	171.33	148.41	513.10	552.07	695.73
	Other Income	0.58	0.12	0.46	0.79	15.10	17.98
	Total Income	229.96	171.44	149.27	513.89	567.17	713.71
2	Expenses						
(a)	Cost of materials consumed	48.93	15.61	8.49	80.89	43.64	48.77
(b)	Purchase of stock - In trade	7.49	37.26	-	45.70	-	-
(c)	Change in inventories of Finished goods, work-in-progress and stock-intrade	11.82	(15.57)	-	(3.75)	-	-
(d)	Employee benefits expenses	8.04	9.17	10.33	26.88	28.29	38.75
(e)	Finance Costs	16.83	14.33	11.42	45.24	37.74	49.78
(f)	Depreciation, depletion and amortisation expenses	40.36	39.63	40.36	117.63	116.71	158.22
(g)	Other expenses	105.83	67.31	101.17	233.73	330.09	390.94
	Total Expenses	239.30	167.74	171.77	546.31	556.47	686.47
3	Profit / (Loss) before tax (1-2)	-9.34	3.71	(22.49)	(32.42)	10.71	27.24
4	Tax Expense						
	Current tax	-	-	(6.58)	-	1.78	4.75
	Defered tax	-6.17	(0.28)	0.39	(6.61)	0.92	2.75
	Total Tax Expenses	-6.17	(0.28)	(6.19)	(6.61)	2.70	7.50
5	Total Profit/(loss) After Tax (3-4)	-3.17	3.99	(16.31)	(25.81)	8.00	19.74
6	Other Comprehensive Income (OCI)						
	a) Items That Will Not Be Reclassified To Profit or Loss			-			0.72
	b) Items That Will Be Reclassified To Profit or Loss			-			0.08
7	Total Comprehensive Income/(Loss) for the period (5+6)	-3.17	3.99	(16.31)	(25.81)	8.00	20.54
8	Details of equity share capital						
9	Paid-up equity share capital	460.00	460.00	460.00	460.00	460.00	460.00
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
10	Other Equity						94.71
11	Earnings per share						
12	Earnings per equity share Rs.						
	Basic	-0.07	0.09	(0.35)	(0.56)	0.17	0.43
	Diluted	-0.07	0.09	(0.35)	(0.56)	0.17	0.43
13	Nominal value of share	10.00	10.00	10.00	10.00	10.00	10.00
Disclosure of notes on finance results							
1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th February, 2025 and have been subjected to limited review by the Auditors.							
2) These financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.							
3) The Standalone results of the company are available on the company's website http://caprolactam.co.in/ and also available on the websites of the BSE Ltd. And National Stock Exchange of India Ltd.							
4) Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary. Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary.							
5) The figures in Rs. Lakhs are rounded off to Two Decimals							
Place: Mahad		FOR AND BEHALF OF THE BOARD OF DIRECTORS					
Date: 14/02/2025						 Mrs. Zaver S Bhanushali Managing Director DIN- 00663374	